Nickel Distribution in Early- and Late-Phase Allergic Contact Dermatitis: Insights from Synchrotron Radiation X-Ray Fluorescence
Nickel is one of the most common triggers of allergic contact dermatitis (ACD)—a condition affecting 10% of women and 1–2% of men globally. Despite its prevalence, scientists have long struggled to understand exactly how nickel penetrates skin, accumulates, and triggers the immune system. A 2019 study led by researchers from Anhui University, Peking Union Medical College Hospital, and the Beijing Synchrotron Radiation Facility (BSRF) aimed to fill this gap by mapping nickel’s distribution in early- and late-phase nickel-induced ACD using cutting-edge synchrotron technology.
What the Study Investigated
The team focused on two key questions:
- How does nickel distribute in skin during early vs. late-stage ACD?
- Is nickel present as free ions (Ni²⁺) or bound to proteins in affected skin?
To answer these, they used 40 Hartley guinea pigs, split into:
- Early-phase group: Sensitized and challenged with a 10% nickel sulfate (NiSO₄) solution (to mimic acute reactions).
- Late-phase group: Sensitized with 5% NiSO₄ and challenged with 10% NiSO₄ (to mimic prolonged exposure).
- Control groups: Positive (exposed to a known allergen, DNCB) and negative (saline).
After applying nickel patches, the team used two synchrotron-based tools:
- Synchrotron radiation micro X-ray fluorescence (SR-m-XRF): A non-destructive technique to measure nickel concentration at different skin depths.
- Micro X-ray absorption near-edge spectroscopy (m-XANES): To analyze nickel’s chemical form (free ions vs. protein-bound).
All animal procedures were approved by the Institute of Laboratory Animal Science of Peking Union Medical College, following international ethical standards.
Key Findings
The study uncovered three critical results:
1. Nickel Concentrates in Upper Skin Layers During Early ACD
In the early-phase group (24 hours after challenge), nickel levels were significantly higher in the upper 300 micrometers of skin (the epidermis, the outermost living layer) compared to deeper layers. This aligns with how allergies start: nickel first accumulates in the epidermis, where it interacts with immune cells.
2. Late-Stage ACD Has Uniform Nickel Distribution
In the late-phase group (72 hours after challenge), nickel was evenly distributed across all skin depths. The team suspects this is due to increased blood flow from inflammation—blood carries away nickel-bound proteins, balancing concentrations in deeper tissues.
3. Nickel Binds to Proteins, Not Free Ions
The m-XANES analysis revealed a game-changing detail: Nickel in affected skin was not present as free Ni²⁺ ions (the form in the original nickel sulfate solution). Instead, it was bound to proteins. This suggests nickel’s allergenicity comes from its interaction with skin proteins, not the ions themselves.
What This Means for Nickel Allergy
Nickel-induced ACD is a type IV hypersensitivity reaction, meaning it’s driven by T-cells (immune cells) that recognize nickel as a threat. For this to happen, nickel must:
- Penetrate the stratum corneum (the skin’s protective outer layer).
- Bind to skin proteins to form a “hapten-protein complex” (the immune system’s target).
The study’s findings confirm step 2—nickel doesn’t act alone. It’s the nickel-protein complex that triggers the immune response.
The early vs. late-phase differences also explain why symptoms change over time:
- Early phase: Redness, swelling, and itching (from high nickel in the epidermis).
- Late phase: Thickened skin or scaling (from nickel spreading deeper and triggering chronic inflammation).
Why This Study Matters
This research is a big step forward for two reasons:
1. Non-Destructive Technology for Skin Research
SR-m-XRF and m-XANES are non-invasive, meaning they can analyze skin samples without damaging them. This is a huge advantage over traditional methods (like biopsies), which destroy tissue. Future studies could use these tools to screen for metal-induced skin damage in humans—no needles required.
2. Targeted Treatments for Nickel Allergy
If nickel’s allergenicity depends on protein binding, treatments could focus on blocking that interaction (e.g., creams that bind nickel before it attaches to skin proteins). The study also highlights the need for more research into which proteins nickel binds to—this could unlock new therapies for severe cases.
Original Study Details
The study was published in the Chinese Medical Journal in 2019. The authors are:
- Shan-Qun Jiang (Anhui University)
- Xiang-Yu Wu (Anhui University)
- Jin-Lyu Sun (Peking Union Medical College Hospital)
- Guang Chen (Beijing Synchrotron Radiation Facility)
- Rui Tang (Peking Union Medical College Hospital)
- Zhi Li (Peking Union Medical College Hospital)
- Ruo-Yao Wei (Institute of Laboratory Animal Science, CAMS/PUMC)
- Lan Liang (Peking Union Medical College Hospital)
- Xian-Jie Zhou (Peking Union Medical College Hospital)
- Dong-Liang Chen (Beijing Synchrotron Radiation Facility)
- Jun Li (Peking University Laboratory Animal Center)
- Hong Gao (Institute of Laboratory Animal Science, CAMS/PUMC)
- Jing Zhang (Beijing Synchrotron Radiation Facility)
- Zuo-Tao Zhao (Peking University First Hospital)
Read the full study here: doi.org/10.1097/CM9.0000000000000365
Was this helpful?
0 / 0